Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LYL273
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Lyell Immunopharma
Deal Size : $860.0 million
Deal Type : Licensing Agreement
Lyell Immunopharma Acquires Global Rights to Next-Gen CAR T-Cell for Metastatic Colorectal Cancer
Details : Through the licensing deal for LYL273, a Cell & Gene Therapy targeting Guanylyl cyclase-C, the focus is on advancing treatment for metastatic colorectal cancer (mCRC).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : $40.0 million
November 10, 2025
Lead Product(s) : LYL273
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Lyell Immunopharma
Deal Size : $860.0 million
Deal Type : Licensing Agreement
Details : GCC19CART is ICT’s lead product candidate from the company’s CoupledCAR® technology. It has been tested in 35 patients in an IRB-approved trial in China.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
August 18, 2022
Details : ICT will provide updated data on GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, being developed to treat patients with relapsed/refractory metastatic colorectal cancer (R/R mCRC) in a poster presentation.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 26, 2022
Details : GCC19CART, its lead product candidate from the Company’s CoupledCAR® technology, demonstrated meaningful dose dependent clinical activity and an acceptable safety profile in patients with R/R mCRC.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 17, 2022
Details : Clinical Data from one research site for GCC19CART, ICT’s lead solid tumor program, for 3rd line plus relapsed/refractory metastatic colorectal cancer (R/R mCRC) shows patients receiving a dose of 2x10^6 CAR T cells / kg demonstrating a 57% (4/7) objec...
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 21, 2022
GCC19CART for Patients With Metastatic Colorectal Cancer
Details : GCC19CART is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Colorectal Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : GCC19CART
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
The U.S. FDA Approves the First Product Candidate GCC19CART of Stancel Biotechnology
Details : Based on ICT’s proprietary solid tumor CoupledCAR® technology platform, GCC19CART is a CAR T-cell therapy intended to treat refractory or relapsed metastatic colorectal cancer that expresses the target antigen guanylate cyclase 2C (GCC or GUCY2C).
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
September 01, 2021
Lead Product(s) : GCC19CART
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : gucy2c CART Cell
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Anhui Provincial Cancer Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
CART Therapy in Digestive System Tumors
Details : Gucy2c CART Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in clinical studies for the treatment of Digestive System Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : gucy2c CART Cell
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Anhui Provincial Cancer Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
CART Therapy in GUCY2C-positive Digestive Tract Tumors
Details : Gucy2c CART Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Digestive System Neoplasms.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : CD19 CAR-T Cell
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Zhejiang University
Deal Size : Inapplicable
Deal Type : Inapplicable
CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
Details : CD19 CAR-T Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Lymphoma.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
April 18, 2017
Lead Product(s) : CD19 CAR-T Cell
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Zhejiang University
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
